James Meyer, PharmD

Executive Scientific Director
Xeris Pharmaceuticals
Chicago, IL, United States

Disclosure information not submitted.

Presentation(s):

• SAT-346 - A Systematic Review of Biochemical Thresholds Utilized in the Identification and Classification of Hypothyroidism and Its Subtypes

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• MON-390 - XP-8121: Once-Weekly Subcutaneous Levothyroxine Bypassing GI Interactions and Reduced Dose Requirements - Insights from A Phase 2 Study

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT